Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

[1]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[2]  S. Swain,et al.  Clinical aspects of inflammatory breast cancer. , 2005, Breast disease.

[3]  J. Bellon,et al.  Abstract P4-06-01: JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting , 2012 .

[4]  M. Morrow,et al.  Surgical aspects of inflammatory breast cancer. , 2005, Breast disease.

[5]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[6]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[7]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[8]  J. Nemunaitis,et al.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yi Xiao,et al.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.

[10]  H. Hurwitz,et al.  A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors , 2018, OncoTargets and therapy.

[11]  E. Winer,et al.  Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer , 2018, npj Breast Cancer.

[12]  W. Anderson,et al.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Jove,et al.  Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer , 2018, Oncotarget.

[14]  C. Garnett,et al.  U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis , 2012, Clinical Cancer Research.

[15]  G. Rosner,et al.  Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee , 2014, Clinical Cancer Research.

[16]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.